GLUCAGON-LIKE PEPTIDE 1(GLP-1) PHARMACEUTICAL FORMULATIONS

A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not li...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	STEPHANIE GREENE, MARK J. HOKENSON, WAYMAN WENDELL CHEATHAM, COHAVA GELBER, MARY FARIS, ANDREA LEONE-BAY, MARK KING, DAVID BRANDT, KEITH OBERG
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery. Se describe una composición que comprende partículas de péptido 1 tipo glucagón (GLP-1) en combinación con dicetopiperazina (DKP) que es estable tanto in vitro como in vivo. La composición tiene utilidad como una formulación farmacéutica para tratar enfermedades tales como diabetes, cáncer y de obesidad pero no se limita a dichas enfermedades y condiciones. En particular, la composición tiene actividad como una formulación farmacéutica para administración pulmonar.